Streetbeat News

Analyst Ratings

UTZ

B of A Securities analyst Peter Galbo maintains a Neutral rating on Utz Brands (NYSE:UTZ) and lowers the price target from $20 to $13.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 6:36 pm

BJ

DLTR

EYE

OLLI

Goldman Sachs analyst Kate McShane has upgraded Dollar Tree (DLTR) and Ollie's Bargain Outlet (OLLI) to Buy from Neutral, while downgrading BJ's Wholesale Club (BJ) and National Vision Holdings (EYE) to Neutral from Buy. The upgrades are based on strong earnings growth potential and attractive valuations, while the downgrades are due to limited earnings upside and ongoing challenges.

Portfolio Pulse from Nabaparna Bhattacharya

October 17, 2023 | 6:36 pm

BLUE

CRSP

EDIT

Cantor Fitzgerald has downgraded Editas Medicine Inc (EDIT) to Neutral from Overweight due to competition in sickle cell therapy. Editas' EDIT-301 is running two years behind Vertex Pharmaceuticals/CRISPR Therapeutics AG's (CRSP) exa-cel and Bluebird Bio Inc's (BLUE) lovo-cel. The development of EDIT-301 is expected to be associated with limited value creation. EDIT shares are down 4.68% at $6.92.

Portfolio Pulse from Vandana Singh

October 17, 2023 | 6:35 pm

CRSP

VRTX

Cantor Fitzgerald has downgraded CRISPR Therapeutics AG (CRSP) to Neutral from Overweight, citing potential barriers and lower than consensus sales estimates for its sickle cell therapy, exa-cel, developed in partnership with Vertex Pharmaceuticals Inc (VRTX). Despite this, the analyst expects a positive recommendation for exa-cel due to its favorable benefit-risk profile. CRSP's stock performance is expected to be closely tied to its product lineup as gene editing technology becomes more common.

Portfolio Pulse from Vandana Singh

October 17, 2023 | 6:33 pm

HUBS

Keybanc Capital Markets analyst Michael Turits has reiterated the Overweight rating on HubSpot, Inc. (NYSE:HUBS), but lowered the price target to $593 from $660. Turits has also lowered 2024/2025 estimates following the third quarter HubSpot Elite partner conversations that weakened relative to the analyst's second quarter checks. The analyst cited macro-market uncertainty and increasing competition as HubSpot moves upmarket as reasons for the lowered estimates.

Portfolio Pulse from Nabaparna Bhattacharya

October 17, 2023 | 6:31 pm

TGT

Unusual options activity has been observed for Target (NYSE:TGT), with a large position indicating a bullish stance. The sentiment among these big-money traders is split between 56% bullish and 43% bearish. The price range targeted by these traders over the last 3 months is from $85.0 to $120.0. Analysts from Truist Securities, HSBC, Stifel, and B of A Securities have given their ratings and price targets for Target.

Portfolio Pulse from Benzinga Insights

October 17, 2023 | 6:31 pm

MNST

B of A Securities analyst Peter Galbo maintains a Buy rating on Monster Beverage (NASDAQ:MNST) but lowers the price target from $63 to $58.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 6:30 pm

KO

B of A Securities analyst Bryan Spillane has maintained a 'Buy' rating on Coca-Cola (NYSE:KO) but lowered the price target from $74 to $60.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 6:28 pm

CNK

DIS

Roth MKM analyst Eric Handler has maintained a Neutral rating on Cinemark Holdings Inc (CNK) with a $20 price target. The analyst noted that Cinemark's box office results have exceeded projections in all three quarters of this year, leading to positive free cash flow and a strengthened balance sheet. However, ongoing Hollywood labor issues could stall this momentum. The analyst also raised concerns about the impact of Hollywood's lengthy work stoppage on the visibility of North American box office growth.

Portfolio Pulse from Shivani Kumaresan

October 17, 2023 | 6:24 pm

COCO

B of A Securities analyst Bryan Spillane has maintained a Neutral rating on Vita Coco (NASDAQ:COCO) and lowered the price target from $32 to $29.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 6:23 pm